News

Part B of MoveDMD Trial Shows Mixed Efficacy Results for CAT-1004 as Duchenne Treatment

Catabasis Pharmaceuticals reported mixed topline data from Part B of the MoveDMD trial evaluating the safety and efficacy of CAT-1004 (edasalonexent) in treating Duchenne muscular dystrophy (DMD) patients. MoveDMD is a three-part, multisite Phase 1/2 trial (NCT02439216) evaluating the efficacy, safety, and the pharmacodynamics (PD) and pharmacokinetics (PK),…

Yale New Haven Children’s Hospital Clinic Named Certified Duchenne Care Center

Yale New Haven Children’s Hospital’s (YNHCH) Muscular Dystrophy Program has been named a Certified Duchenne Care Center by Parent Project Muscular Dystrophy (PPMD), a nonprofit organization dedicated to ending Duchenne muscular dystrophy (DMD). PPMD’s Certified Duchenne Care Center Program, which was started in 2014, supports standardized, comprehensive…